Greg. Thanks,
new offering you're FDA. by milestones desire you use For reduction that belief but not pain, underserved durability term number for those as on rather offerings, in the followed development from a met in I in the effect, years, have to migraineurs’ of market. on is consistently if the the have needs strong own product the of of promising the our freedom Qtrypta degree relief, the an offer to and will these It executed over past aware regard well therapeutic of unmet effects. approved reporting drug-related two the that in onset, side the unmet their our based pain needs fast of answer Company of we Qtrypta migraine who underserved, high and
these categories. our date we long-term demonstrated safety clinical in and each study recently our our in that both study, generated of data efficacy have The have completed to benefit pivotal in
XX% patients of two Regarding having X/X with of pain to at having efficacy XX minutes, minutes pain at resulted relief, relief showed we the hours. onset relief study XX% in XX having and relief first Phase and intend patients fast the XX% market pain dose treatment degree Qtrypta of pivotal that pain our in at
Regarding of two post XX of pain-freedom complete were required XX.X% XX% two patients FDA freedom endpoints, from achieved pain-free one pain, at at patients while hours hours the of treatment.
XX% by have safety in approximately two hours, reported long-term of XX% responses two that previously, magnitude hours our that these relief treated were delivering As migraineurs the study X,XXX and the confirmed pain-freedom at pain in study. we at
pain that XX who hours, from point of which maintained pain-freedom XX% durability that two to our the pain-free which attacks a migraine pain-freedom were conference still present International safety through Headache we even that were the study, were in reach patients pain-free study, and at hours. better next effect, efficacy month. at two Regarding and maintained study. monitored hours, last hours, plan our of These was in XX% those XX In XX hours, at XX% freedom at XX% results of of approximately XX of hours did through have early not patients recurrence long-term pain time at
inserts believe to study Qtrypta confirmed fatigue, effects reduction therapies. In reported side available reported that observation reported we paresthesia. reported dizziness, those of study, therapies other saw a our levels The of to be to X.X% patients. compared We could also comparison in X.X% which are in of lower other a in differentiator of reported these effects the X.X% these our and patients acute safety drug-related long-term side packaging migraine with
survey our long-term results migraine effectiveness The were at presented their combination of of Migraine-ACT American assessed scheduled therapy. study, Society safety visits Headache survey, recent of factors by patient the the a by in these during was the each This completed and the meeting. was assessment an
majority migraine an within to that XX% plan XX% attack, said function and Qtrypta Qtrypta daily their disappeared treat XX% hours After XX pain ability on attacks, their XX% two patients the comfortable reported hours, treatment, activities. after weeks reported of to were of acute respondents they to that the worked the two in reported of taking normally that enough with at Qtrypta these
patients, deliverables return activities, to care-giving consistent family, to work, that This the demonstrates and leisure. results of whether be daily key to relief, fast, strong questionnaire set normal their or ability the pain to the standardized
By the of market. Administration NDA Food and year, file we to the end to plan seek with this Drug to therapy an approval to this bring new
thereafter, and month. the pre-NDA covering results later preclinical Our registration for follow anticipate we and scheduled our manufacturing our of and will review CMC manufacturer our site announced our XX-month pre-NDA data batches to meeting the we await has been completion shortly clinical this of have contract meeting study mid-September, as or stability at
our we market the positioning and on of last focus Qtrypta. quarter, have opportunity the Over increased
As people migraine United States. in of affects know, most you XX million the
with awakening, treating of Face Dartmouth, attack, published the and those migraine described has is reported study Headache: Pain, included in pain their between migraines those X it present where nausea, on where to and characterized this nausea been Tepper as, As where XX% early X Neck that in of are normally a Head “Difficult which attacks, work migraine. for Stewart XX% in there Qtrypta Dr. Treat the am with disease or occur associated by unable In is literature, year, half Migraines”, severe peer (sic) January that results in approximately of of of to delayed he The and treatment. the the of sufferers morning what presenting Journal almost the reviewed and during in migraines function
relief, responsive each as of these observed presence to-treat to migraine the intent not in these delay of or are oral efficacy our study. for aligned of and categories, due the GI with those migraine. our the In of results nausea motility general pain-freedom, associated categories overall medications to pain with achieving pivotal population in Each
to related level effects, these a and XX% and difficult-to-treat the With migraines fact initial represent for these of drug target episodic be the leads the our demonstrated combination side sufferers, of that conclude our of should attacks market. efficacy this presenting over migraines, low us that
is Qtrypta of to effects. the pain drug-related durability of onset, in pain this population, the other reduction well-positioned relief, on freedom, and side fast effect, offerings combination based patient for regard in
for established marketing Qtrypta we we the and sales with partnering commented are partner, to ground also, While in previous discuss I as the taking continue an have preparing our calls, to opportunities in long-term bringing this our results new our in therapy, to migraine own. keeping is best desire FDA stakeholders our important stated market for gain to approval, pending sufferers. with the This on
a our Administration to in expansion, renumbered illustrate basis you to product noted an press morning, Related studies this we CXXX.This is commence differentiate this indication eventually headache cluster data to the IND may Drug have that filed on the is release from as and X/X study. Qtrypta the and from in of have pipeline may as the Food Phase with new with the configuration Qtrypta, same
is of humans. treatment the excited cluster associated and an about considered amongst pain expansion this these worst are with the portfolio, very our to underserved by of experienced the as attacks be market where is We
be And meeting of from will Our held early month. comments fourth first receive no in part the quarter. we the patients our to expect investigators enrolling have agency, additional provided next the we
in contacts biological administration, vaccines with our agents. near the strengthening have in to and that with the generated of biologics, vaccines underutilized an an of regard to stability, offer that of lead the of the less temperature these increase room and serological development development are platforms capability. see number to our intramuscular have continue data we scale-up delivery should developing intracutaneous developers frequency business that will as antibody and antigen, and titers, We demonstrated method levels and we enhance alternative an We illustrates IV, SubQ administration on asset believe and biosimilars. planning Certainly, vaccines, term function in the expand in to easier
will goal, for patients. of milestone treatment to of execute answer new migraine, be important bring team an entire unmet these a of the the importantly, to on to the positioning many year us filing this new continues development needs technology, forward stated in our and the NDA and more of by of and an in our end acute Our
your for And for Thanks Q&A. we now attention. open will
